Search results
Amgen Soars as CEO Touts Experimental Obesity Drug Progress
Bloomberg via Yahoo Finance· 4 hours ago(Bloomberg) -- Amgen Inc.’s shares soared after its chief executive officer said he was “very...
Launching an Obesity Medicine Practice? Key Considerations
Medscape· 13 hours agoWith the demand for anti-obesity drugs continuing to soar and the provision of supportive care that...
...Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY): Anti-Obesity Drug Market Could Reach Double Current...
The Wall Street Transcript· 5 days agoCiti Research Health Care Analyst Andrew Baum, M.D., maintains a “buy” recommendation on GLP-1...
Amgen touts new data for drug MariTide, moving rapidly into Phase 3 work
Endpoints News· 20 hours agoAmgen said that an interim look at a Phase 2 trial of its anti-obesity drug MariTide had left the...
Blockbuster weight loss drug Wegovy's sales just doubled — and could heat up even more with a price...
Business Insider· 12 hours agoSales of Wegovy more than doubled in the first quarter year-on-year, to $1.3 billion.
Stock Market Today: Apple powers tech; stock surge after softer jobs data
TheStreet via Yahoo Finance· 7 hours agoDow component Amgen (AMGN) shares were also on the move, rising nearly 15% after the biotech...
Here's what's driving Friday's stock action in Apple, Coterra and Eli Lilly
CNBC· 2 hours agoEvery weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20...
Wegovy & other GLP-1 drugs to get coverage under Medicare Part D
AARP· 2 days agoThe FDA recently approved a new use for Wegovy (semaglutide), the blockbuster anti-obesity drug, to reduce the risk of heart attacks ...
Biotech’s bind over China bill
Politico· 2 hours agoBut while those products drove growth, both companies still face issues meeting demand. Novo executives declined to speculate on the extent to which the company expects to scale supply of < ...
Novo Nordisk Stock Falls After Pricing Pressure Mounts for Wegovy
The Wall Street Journal· 1 day agoNovo Nordisk’s American depositary receipts slipped nearly 3%, despite reporting higher quarterly...